Press releases

Novasep continues to lead and innovate in the development and production of pharmaceutical molecules and announces the launch of a new industrial-scale HPLC system that is faster, safer, and more productive than ever: Hipersep® Process M

• A new unit designed for high-pressure chromatography up to 100 bars, suitable for purification processes requiring high temperatures (up to 85°C)
• A wide range of flow rates (20 to 500 l/h) for more flexibility
• A sanitary design for faster, easier, and more efficient cleaning

• The agreement covers the cGMP clinical manufacturing of a next-generation ADC drug candidate
• Novasep’s Le Mans site, in France, has already manufactured the ADC for Exelixis’ ongoing phase 1 clinical trial
• Novasep leverages its ADC bioconjugation expertise and process development capabilities in support of promising new cancer treatments

• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created

Une nouvelle étape pour l’avancée d’un projet innovant et structurant au service de la Bioproduction de santé française

• Novasep continues to consolidate its position as a leading CDMO for the production of innovative and targeted molecules to treat cancer by investing in additional capacity
• Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
• More than 30 full-time jobs to be created

• The Group recorded sales of €394M (+46%) and an EBITDA of €63M (+174%)
• Novasep has now completed its Rise-2 strategic plan, a full two years ahead of schedule
• Full deleveraging is in progress following the divestment of the Viral Vector Manufacturing Business in early 2021

Novasep Holding S.A.S. (“Novasep”) has today announced the results of its offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).

Novasep Holding S.A.S. (“Novasep”) has today commenced an offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).